Shares of Absci Corporation (ABSI) experienced a dramatic surge of approximately 35% in afternoon trading on Wednesday, reaching $10.01, following the release of early safety data for its experimental hair-loss antibody, ABS-201. The positive results from the Phase 1 trial, combined with a concurrent announcement of a $100 million stock offering, propelled the stock to an intraday high of $10.97 on heavy volume of about 33.8 million shares.
Phase 1 Safety Data and Trial Details
The Vancouver, Washington-based AI-driven drug discovery company reported that ABS-201 was well tolerated in the single-ascending-dose portion of its first-in-human Phase 1 study. As of the June 8 data cutoff, no serious adverse events were observed, with the majority of treatment-emergent adverse events being mild in nature. The trial enrolled 32 healthy adults, divided into four cohorts receiving single intravenous doses of either ABS-201 or placebo at 150 mg, 450 mg, 900 mg, or 1800 mg.
Chief Medical Officer Ransi Somaratne expressed optimism, stating, "We are particularly encouraged by the emerging safety, pharmacokinetic, and immunogenicity profile observed to date." Pharmacokinetics refers to how the drug moves through the body, while immunogenicity assesses whether the immune system reacts against the drug. The estimated half-life of ABS-201 was at least 65 days, suggesting a potential dosing regimen of only two or three injections over six months, pending further data.
Advancing to Multiple-Dose Trials and Efficacy Expectations
Having completed the single-dose stage, Absci has now progressed to the multiple-dose portion of the trial, which involves repeated subcutaneous injections in patients with androgenetic alopecia, commonly known as male- and female-pattern hair loss. The company anticipates interim proof-of-concept efficacy data in the second half of 2026, with additional results expected in early 2027. These data points will be critical in determining whether ABS-201 can meaningfully stimulate hair growth.
0 Million Stock Offering to Fund Development
In a separate regulatory filing, Absci disclosed that it has priced a stock offering of 13,495,277 shares at $7.41 per share, aiming to raise approximately $100 million in gross proceeds before underwriting discounts and expenses. The offering includes participation from notable investors such as Eli Lilly and investment funds including Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile. Jefferies, J.P. Morgan, TD Cowen, and Guggenheim Securities are serving as joint bookrunners. The offering is expected to close around June 25.
The company intends to use the net proceeds to fund the development of ABS-201 for androgenetic alopecia and endometriosis, as well as for general working capital. As of the end of March, Absci reported $125.7 million in cash, cash equivalents, and marketable securities.
Competitive Landscape and Market Context
Absci faces established competition in the hair-loss market, with minoxidil and finasteride remaining the only FDA-approved drugs for androgenetic alopecia. However, both treatments have efficacy limitations and side-effect concerns. Another emerging player is Hope Medicine, which is developing HMI-115, a prolactin-receptor antibody. In 2024, HopeMed reported that its Phase 1b trial in 16 patients showed an average hair-count gain among men, with founder Rui-Ping Xiao stating that "prolactin receptor blockade can promote hair growth in patients with androgenic alopecia."
Despite the encouraging safety data, Absci has yet to demonstrate that ABS-201 can actually grow hair in a controlled trial. The current results are from a small early-stage study and represent only blinded safety data. The company also cautioned that interim or preliminary results may not match final outcomes, and risks such as delays, enrollment difficulties, adverse events, or lack of efficacy could impede the program's progress.
